Walpar Nutritions (WALPAR)₹25.00−4.21%Pharmaceuticals
In the Mar 2026 quarter (consolidated), Walpar Nutritions reported sales of ₹42.35 Cr, up 7.8% from Mar 2025, and net profit of ₹1.49 Cr, up 6.4% year on year. For the year to Mar 2026, sales were ₹78.88 Cr and net profit ₹2.99 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 18.66 | 31.20 | 31.43 | 32.59 | 39.29 | 36.57 | 42.35 |
| Expenses | 16.18 | 29.26 | 28.72 | 30.00 | 36.24 | 33.63 | 38.72 |
| Operating Profit | 2.51 | 2.00 | 2.77 | 2.65 | 3.09 | 2.95 | 3.73 |
| OPM % | 13.5% | 6.4% | 8.8% | 8.2% | 7.9% | 8.1% | 8.9% |
| Other Income | 0.28 | 0.07 | 0.17 | 0.32 | −0.05 | 0.14 | 0.14 |
| Interest | 0.37 | 0.34 | 0.35 | 0.27 | 0.04 | 0.31 | 0.51 |
| Depreciation | 1.06 | 0.93 | 0.88 | 0.89 | 0.93 | 0.99 | 1.01 |
| Profit before tax | 1.35 | 0.81 | 1.70 | 1.82 | 2.08 | 1.78 | 2.34 |
| Tax % | 15.6% | 19.9% | 23.1% | 22.1% | 32.8% | 15.2% | 27.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 1.15 | 0.64 | 1.30 | 1.40 | 1.40 | 1.49 | 1.49 |
| EPS (Rs) | 1.08 | 0.44 | 1.27 | 1.38 | 1.12 | 1.38 | 1.27 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 6.08 | 26.80 | 35.22 | 62.61 | 71.86 | 78.88 |
| Expenses | 5.63 | 25.80 | 31.76 | 57.96 | 66.19 | 72.38 |
| Operating Profit | 0.47 | 1.03 | 3.50 | 4.76 | 5.73 | 6.67 |
| OPM % | 7.6% | 3.8% | 10.0% | 7.6% | 8.0% | 8.5% |
| Other Income | 0.00 | 0.03 | 0.33 | 0.23 | 0.28 | 0.27 |
| Interest | 0.19 | 0.49 | 0.80 | 0.68 | 0.30 | 0.81 |
| Depreciation | 0.13 | 0.29 | 1.90 | 1.80 | 1.81 | 2.01 |
| Profit before tax | 0.17 | 0.29 | 1.12 | 2.50 | 3.89 | 4.11 |
| Tax % | 6.2% | −32.2% | 27.0% | 22.1% | 27.8% | 21.7% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 |
| Net Profit | 0.16 | 0.37 | 0.82 | 1.95 | 2.80 | 2.99 |
| EPS (Rs) | 0.23 | 0.43 | 0.66 | 1.69 | 2.48 | 2.64 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 3.34 | 4.55 | 4.54 | 4.71 | 9.42 | 9.41 |
| Reserves | 1.43 | 6.44 | 7.15 | 9.47 | 7.15 | 9.50 |
| Borrowings | 7.50 | 7.26 | 10.31 | 8.32 | 7.87 | 16.81 |
| Other Liabilities | 5.70 | 9.80 | 12.23 | 14.59 | 22.88 | 30.25 |
| Total Liabilities | 17.97 | 28.05 | 34.23 | 37.09 | 47.32 | 65.97 |
| Fixed Assets | 1.69 | 2.00 | 10.09 | 10.16 | 10.61 | 12.17 |
| CWIP | 1.21 | 4.47 | 0.01 | 0.01 | 0.02 | 0.04 |
| Investments | 0.00 | 0.50 | 0.01 | 1.87 | 1.87 | 2.87 |
| Other Assets | 15.07 | 21.08 | 24.12 | 25.05 | 34.82 | 50.89 |
| Inventories | 4.32 | 5.92 | 8.49 | 9.15 | 10.52 | 15.25 |
| Trade receivables | 7.14 | 9.08 | 12.44 | 13.40 | 21.10 | 23.37 |
| Cash & equivalents | 0.97 | 0.45 | 0.53 | 0.50 | 1.58 | 4.91 |
| Total Assets | 17.97 | 28.05 | 34.23 | 37.09 | 47.32 | 65.97 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | −0.32 | −1.09 | 1.11 | 5.36 | 4.07 | 1.84 |
| Cash from investing activity | −2.03 | −6.16 | −3.45 | −3.62 | −2.31 | −6.59 |
| Cash from financing activity | 2.96 | 6.72 | 2.43 | −1.78 | −0.69 | 8.09 |
| Net cash flow | 0.63 | −0.52 | 0.08 | −0.04 | 1.09 | 3.35 |
| Capex | 1.85 | 3.83 | 5.22 | 1.86 | 2.27 | 3.58 |
| Free cash flow | −2.18 | −4.93 | −4.15 | 3.49 | 1.79 | −1.77 |
| CFO / OP % | −67.1% | −99.1% | 34.0% | 115.9% | 81.9% | 40.9% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 430 | 123 | 129 | 77 | 107 | 108 |
| Inventory days | 369 | 103 | 129 | 67 | 68 | 94 |
| Days payable | 455 | 135 | 144 | 73 | 108 | 136 |
| Cash conversion cycle | 344 | 92 | 114 | 73 | 67 | 66 |
| Working capital days | 316 | 62 | 88 | 44 | 42 | 41 |
| ROCE % | — | 4.9% | 8.9% | 12.9% | 16.1% | 14.9% |
For the Mar 2026 quarter, Walpar Nutritions reported sales of ₹42.35 Cr, up 7.8% year on year and net profit of ₹1.49 Cr, up 6.4% year on year. The operating margin was 8.9%.
Walpar Nutritions' sales for the year to Mar 2026 were ₹78.88 Cr.
Net profit for the year to Mar 2026 was ₹2.99 Cr. Earnings per share over the same trailing period were ₹2.64.
Walpar Nutritions reported borrowings of ₹16.81 Cr at Mar 2026, against cash and equivalents of ₹4.91 Cr.
Cash from operations was ₹1.84 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹1.77 Cr.